Trending stocks today
Natera (NTRA-Q)
NASDAQ:NTRA
167.12
0.67
(0.40%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
Natera, a biotech company with symbol NTRA-Q, is gaining attention from experts for its accurate cancer testing and fast growth. With expectations of reaching cash-flow positivity this year, the company is making a positive impression on investors and experts alike. The reviews suggest that Natera is a promising player in the biotech industry, with a focus on impactful and accurate testing capabilities for cancer and other medical conditions.
$89.265
Owned
- «
- ‹
- 1
- ›
- »
Natera(NTRA-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Natera(NTRA-Q) Frequently Asked Questions
What is Natera stock symbol?
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
Is Natera a buy or a sell?
In the last year, 1 stock analyst published opinions about NTRA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Is Natera a good investment or a top pick?
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Why is Natera stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Natera worth watching?
1 stock analyst on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
What is Natera stock price?
On 2024-12-11, Natera (NTRA-Q) stock closed at a price of $167.12.
A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.